Expression of chemokine CCL20 in ulcerative colitis

Zhang,Haifeng; Zhong,Wane; Zhou,Guoxiong; Ding,Xiaoling; Chen,Haiqing

doi:10.3892/mmr.2012.1088

Expression of chemokine CCL20 in ulcerative colitis

Authors:
- Haifeng Zhang
- Wane Zhong
- Guoxiong Zhou
- Xiaoling Ding
- Haiqing Chen
View Affiliations

Affiliations: Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong 226001, P.R. China, Department of Gastroenterology, The Sixth Hospital of Ningbo, Zhejiang 315040, P.R. China
Published online on: September 20, 2012 https://doi.org/10.3892/mmr.2012.1088
Pages: 1255-1260

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the current study was to investigate the expression of chemokine CCL20 in ulcerative colitis (UC) patients and in dextran sulfate sodium (DSS)-induced experimental colitis in mice. The expression of the CCL20 protein in colonic mucosa was detected in 65 UC patients and in 30 normal patients. A total of 40 female BALB/c mice were divided into a control and model group; the latter was fed a 5% DSS solution ad libitum for 7 days to induce experimental colitis. The disease activity index (DAI) and histological score were assessed and the expression of CCL20 mRNA and protein was determined. CCL20 was expressed in the UC group. It was either weakly expressed or not expressed in the normal control group. Additionally, the expression of CCL20 in the UC group was significantly higher compared with that in the control groups (P<0.01). The expression levels of CCL20 mRNA and protein were significantly increased in the model group compared with those in the control group (P<0.01) and positively correlated with the severity of colonic inflammation. The results from the present study demonsrtate that CCL20 positively correlates with UC. CCL20 may play a significant role in local damage and pathological changes in UC and may serve as a potential target for therapy.

View Figures

View References

1	Stevceva L, Pavli P, Husband AJ and Doe WF: The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it. BMC Clin Pathol. 1:32001. View Article : Google Scholar : PubMed/NCBI
2	Bennink RJ, Hamann J, de Bruin K, ten Kate FJ, van Deventer SJ and te Velde AA: Dedicated pinhole SPECT of intestinal neutrophil recruitment in a mouse model of dextran sulfate sodium-induced colitis. J Nucl Med. 46:526–531. 2005.PubMed/NCBI
3	Hyun JG, Lee G, Brown JB, et al: Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Dis. 11:799–805. 2005. View Article : Google Scholar : PubMed/NCBI
4	Rivera-Nieves J, Ho J, Bamias G, et al: Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology. 131:1518–1529. 2006. View Article : Google Scholar : PubMed/NCBI
5	Farooq SM, Stillie R, Svensson M, Svanborg C, Strieter RM and Stadnyk AW: Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther. 329:123–129. 2009. View Article : Google Scholar : PubMed/NCBI
6	MacDermott RP: Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol. 31:907–916. 1996. View Article : Google Scholar : PubMed/NCBI
7	Lee HJ, Choi SC, Lee MH, et al: Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment. Inflamm Bowel Dis. 11:1070–1079. 2005. View Article : Google Scholar
8	ten Hove T, Drillenburg P, Wijnholds J, Te Velde AA and van Deventer SJ: Differential susceptibility of multidrug resistance protein-1 deficient mice to DSS and TNBS-induced colitis. Dig Dis Sci. 47:2056–2063. 2002.PubMed/NCBI
9	te Velde AA, de Kort F, Sterrenburg E, et al: Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 13:325–330. 2007.PubMed/NCBI
10	Murano M, Maemura K, Hirata I, et al: Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol. 120:51–58. 2000. View Article : Google Scholar
11	Boirivant M, Fuss IJ, Ferroni L, De Pascale M and Strober W: Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis. J Immunol. 166:3522–3532. 2001. View Article : Google Scholar
12	Koga H, Sakisaka S, Ohishi M, et al: Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology. 29:688–696. 1999. View Article : Google Scholar : PubMed/NCBI
13	Banks C, Bateman A, Payne R, Johnson P and Sheron N: Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn’s disease. J Pathol. 199:28–35. 2003.PubMed/NCBI
14	Watanabe S, Yamakawa M, Hiroaki T, Kawata S and Kimura O: Correlation of dendritic cell infiltration with active crypt inflammation in ulcerative colitis. Clin Immunol. 122:288–297. 2007. View Article : Google Scholar : PubMed/NCBI
15	Uguccioni M, Gionchetti P, Robbiani DF, et al: Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol. 155:331–336. 1999. View Article : Google Scholar : PubMed/NCBI
16	MacDermott RP, Sanderson IR and Reinecker HC: The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 4:54–67. 1998.PubMed/NCBI
17	Buanne P, Di Carlo E, Caputi L, et al: Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol. 82:1239–1246. 2007. View Article : Google Scholar : PubMed/NCBI
18	Zimmerman NP, Vongsa RA, Wendt MK and Dwinell MB: Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis. 14:1000–1011. 2008. View Article : Google Scholar : PubMed/NCBI
19	Sartor RB: Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 106:533–539. 1994.PubMed/NCBI
20	Ashwood P, Harvey R, Verjee T, Wolstencroft R, Thompson RP and Powell JJ: Functional interactions between mucosal IL-1, IL-ra and TGF-beta 1 in ulcerative colitis. Inflamm Res. 53:53–59. 2004.PubMed/NCBI
21	Izadpanah A, Dwinell MB, Eckmann L, Varki NM and Kagnoff MF: Regulated MIP-3alpha/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. Am J Physiol Gastrointest Liver Physiol. 280:G710–G719. 2001.PubMed/NCBI
22	Jin Y, Fuller L, Ciancio G, et al: Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow. Hum Immunol. 65:93–103. 2004. View Article : Google Scholar : PubMed/NCBI
23	Kaser A, Ludwiczek O, Holzmann S, et al: Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 24:74–85. 2004. View Article : Google Scholar : PubMed/NCBI
24	He C, Zhang SL, Hu CJ, Tong DW and Li YZ: Higher levels of CCL20 expression on peripheral blood mononuclear cells of chinese patients with inflammatory bowel disease. Immunol Invest. 39:16–26. 2010. View Article : Google Scholar : PubMed/NCBI